​​​​AACR Tobacco and Cancer Subcommittee

The AACR Tobacco and Cancer Subcommittee was convened in 2009 to foster scientific and policy initiatives to reduce the incidence of disease and mortality due to tobacco use.

Tobacco use is the leading preventable cause of premature mortality, killing more than five million people worldwide every year. It has a particularly profound impact on cancer incidence and mortality. Indeed, tobacco use is causally associated with 18 different cancers, including lung, head and neck, stomach, pancreas, and cervical cancers, and alone tobacco accounts for 30 percent of all cancer deaths.

Comments to the FDA on Nicotine Replacement Therapies from the AACR Tobacco and Cancer Subcommittee ​

On January 26, 2018 the U.S. Food and Drug Administration (FDA) held a public hearing on the FDA’s approach to evaluating the safety and efficacy of nicotine replacement therapy (NRT) products, including how to promote innovation in these products and how they should be used and labeled. AACR Tobacco and Cancer Subcommittee member Dorothy K. Hatsukami, PhD, Associate Director of Cancer Prevention and Control at the University of Minnesota Masonic Cancer Center, presented a summary of the AACR’s Tobacco and Cancer Subcommittee’s comments to the FDA. On February 15, the AACR Tobacco and Cancer Subcommittee submitted comments in response to the FDA's Approach to Evaluating Nicotine Replacement Therapies (Docket No. FDA-2017-N-6529).

Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research​

In this Special Report published online on Feb. 17, 2016, ​in Clinical Cancer Research, the NCI-AACR Cancer Patient Tobacco Us​e Assessment Task Force outlines priority research areas and describes recommendations for assessment items and the timing of assessment related to tobacco use among cancer patients.

The State of Ends Science​ Policy Webinar

Nov. 20, 2015

Electronic nicotine delivery systems (ENDS), which include electronic cigarettes (e-cigarettes) have become increasingly popular among adults and youth and have been suggested as potential tobacco cessation products.

In this webinar, our panel of experts will provide an updated state of knowledge about the safety and efficacy of ENDS from a scientific research standpoint. We will also continue discussions that began at the AACR Annual Meeting 2015 and continued at the congressional briefing on ENDS in May 2015 by inviting questions from the audience.​

Learn more about this webinar.

Electronic Cigarettes: What You Don't Know Can Hurt You​
AACR Congressional Briefing

​On May 14, 2015, the AACR in cooperation with Representative Jackie Speier (D-Calif.) and Senator Richard Blumenthal (D-Conn.) sponsored a congressional briefing entitled, "Electronic Cigarettes: What You Don't Know Can Hurt You." 

While the merits of electronic cigarettes and other electronic nicotine delivery systems (ENDS) as smoking cessation tools remain the subject of intense research and discussion, the AACR and other organizations have become concerned with the rising population of these devices, particularly among underage youth, in the absence of hard data demonstrating their safety.​

Read more about the briefing.

Tobacco Control and Electronic Nicotine Delivery Systems (ENDS)​​
Science Policy session at the AACR Annual Meeting 2015

​​Recommendations for the Regulation of Electronic Cigarettes
An AACR-ASCO Policy Statement

On Jan. 8, 2015, the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) released a joint statement to guide policy makers in how to best minimize the potential negative consequences of electronic nicotine delivery systems (ENDS) without undermining their potential use as a smoking cessation tool.

Electronic cigarettes (e-cigarettes) and other ENDS, which are capable of delivering a nicotine solution in aerosol form, have been suggested as potential tobacco cessation interventions and safer alternatives to cigarettes. At the present time, however, there are insufficient data on the health consequences of e-cigarette use, their value as tobacco cessation aids, and their effects on the use of combustible tobacco products by smokers and nonsmokers.

Read the recommendations

Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology

​Tobacco Use by Cancer Patients: An AACR Policy Statement

Tobacco use not only causes cancer, but it also interferes with cancer treatment and leads to poorer outcomes. The AACR has drafted a policy statement with recommendations related to tobacco use by cancer patients which calls for universal tobacco use assessment, provision of cessation treatment to all cancer patients, and the evaluation of tobacco use as a confounding factor in cancer clinical trials.

Assessing Tobacco Use by Cancer Patients and Facilitating Cessation: An American Association for Cancer Research Policy Statement

Presentation on the AACR’s tobacco policy statement by Tobacco and Cancer Subcommittee Chair, Roy S. Herbst, MD, PhD

The Science Behind Tobacco Control

The Family Smoking Prevention and Tobacco Control Act (FSPTC) of 2009 created the FDA Center for Tobacco Products (CTP) and for the first time in U.S. history created a framework for the regulation of tobacco products. The CTP’s mission to reduce the public health harms of tobacco use through evidence-based regulation of tobacco products relies on continual research as new tobacco products emerge and our understanding of the biochemical and psychological responses to tobacco use improves. The AACR is committed to working with the FDA and other policy makers to improve our understanding of the public health impact of tobacco and to reduce global tobacco use.

AACR Documents

Co-signed Documents​     


Archived News 







Subcommittee Members

Roy S. Herbst, MD, PhD, Chairman

Denise Aberle, MD
Thomas H. Brandon, PhD
Geoffrey T. Fong, PhD
Jennifer Rubin Grandis, MD
Ellen R. Gritz, PhD
Dorothy K. Hatsukami, PhD
Ernest Hawk, MD, MPH
Waun Ki Hong, MD, DMSc (hon)
Fadlo R. Khuri, MD
Scott J. Leischow, PhD
Peter G. Shields, MD
Benjamin Toll, PhD
Kasisomayajula (Vish) Viswanath, PhD
Graham Warren, MD, PhD
Stephanie Land, PhD, ex officio

AACR Staff Contact

Nicole Boschi, PhD
Senior Science Policy Analyst  

Email or call 215-446-7275

Top of page